United Kingdom
United Kingdom

The 'go to' European specialist pharma company

Our Vision 2020


  • Norgine is the ‘Go to’ EU specialist pharma company
  • For the last 20 years, Norgine has been successful in building an infrastructure that understands the EU pharma market
  • Norgine is able to develop and  commercialise products across Europe
  • Norgine partners in many different ways


Living in the shadow of hepatic encephalopathy


First ever UK survey of patient experiences with hepatic encephalopathy commissioned* by the British Liver Trust and Liver4Life, shows that out of 33 anonymous respondents;

  • Over half of respondents had been hospitalised, or seen their loved one hospitalised in the previous 12 months as a result of a hepatic encephalopathy episode
  • One in three had been hospitalised multiple times, and some even more than six times in one year
  • The average length of stay in hospital for most patients (70%) was up to 10 days. For some (12%), a typical hospital stay was equivalent to a month or more1

*Survey supported by an unrestricted educational grant from Norgine.

1Norgine data on file: Results of the 2014 survey of patients and carers with hepatic encephalopathy


Xray image showing hepatic encephalopathy, a chronic condition of the liver

Fast Facts: Hepatic encephalopathy

  • Around 29 million people in Europe suffer from a chronic liver condition.[i]
  • Hepatic encephalopathy is a worsening of brain function that occurs when the liver is no longer able to remove toxic substances in the blood.[ii]
  • Liver disease patients with hepatic encephalopathy have almost double the risk of dying and are admitted to hospital three times more often for illnesses directly related to their liver disease, compared with those patients without hepatic encephalopathy.[iii]

[i] Blachier M, Leleu H, Peck-Radosavljevic et al. The burden of liver disease in Europe. A review of available epidemiological data. EASL, 2013
[iii] Orr J.G. et al. Resource use associated with hepatic encephalopathy in patients with liver disease. International Liver Congress 2014, Abstract P478



  • Who does constipation affect?
  • What is the scale of the problem?
  • Who is at risk of constipation?
  • What is the true cost of constipation?
  • How does constipation impact on daily life?